Physician profile
Christopher Johnson
NPI 1164717211
$1,686.39
in general payments reported to CMS, 2019-2025
17 companies · $455 in 2025
The $455 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $71.72 · 2021: $122 · 2022: $360 · 2023: $239 · 2024: $182 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.58 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $597.04 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $278.79 | 2020-2024 | Tremfya |
| Boston Scientific Corporation | $171.95 | 2022-2023 | Resolution 360 Clip |
| Takeda Pharmaceuticals U.S.A., INC. | $121.55 | 2025 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $102.83 | 2022 | |
| Astellas Pharma US INC | $101.32 | 2023 | Xospata |
| Janssen Biotech, INC. | $89.00 | 2025 | Tremfya |
| Lilly USA, LLC | $83.15 | 2019 | |
| Madrigal Pharmaceuticals | $45.29 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $31.97 | 2024 | Terlivaz |
| Medtronic, INC. | $28.56 | 2025 | Manoscan |
| Novo Nordisk INC | $20.08 | 2025 | Wegovy |
| Celltrion USA INC. | $14.86 | 2025 | Vegzelma |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.